{"id":"NCT01139580","sponsor":"Stiefel, a GSK Company","briefTitle":"The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis","officialTitle":"A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam In The Treatment Of Moderate Plaque-Type Scalp And Body Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2010-12","completion":"2010-12","firstPosted":"2010-06-08","resultsPosted":"2011-09-23","lastUpdate":"2017-01-18"},"enrollment":363,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Calcipotriene Foam","otherNames":[]},{"type":"DRUG","name":"Vehicle Foam","otherNames":[]}],"arms":[{"label":"Calcipotriene Foam","type":"EXPERIMENTAL"},{"label":"Vehicle Foam","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and effectiveness in the treatment of psoriasis on the scalp and on the body.","primaryOutcome":{"measure":"Number of Participants With an Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using the Failure Method","timeFrame":"Week 8","effectByArm":[{"arm":"Calcipotriene Foam","deltaMin":74,"sd":null},{"arm":"Vehicle Foam","deltaMin":44,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":26,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":181},"commonTop":["Application site pruritus","Application site pain","Application site erythema","Erythema","Nasopharyngitis"]}}